CSPC Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
CSPC Pharmaceutical Group has a total shareholder equity of CN¥35.0B and total debt of CN¥706.9M, which brings its debt-to-equity ratio to 2%. Its total assets and total liabilities are CN¥46.3B and CN¥11.3B respectively. CSPC Pharmaceutical Group's EBIT is CN¥7.3B making its interest coverage ratio -31.4. It has cash and short-term investments of CN¥13.8B.
Key information
2.0%
Debt to equity ratio
CN¥706.90m
Debt
Interest coverage ratio | -31.4x |
Cash | CN¥13.76b |
Equity | CN¥35.02b |
Total liabilities | CN¥11.26b |
Total assets | CN¥46.28b |
Recent financial health updates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Sep 15Recent updates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price
Oct 18CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Sep 15CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10
Aug 26CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At HK$0.10
May 27Financial Position Analysis
Short Term Liabilities: 1093's short term assets (CN¥26.7B) exceed its short term liabilities (CN¥10.2B).
Long Term Liabilities: 1093's short term assets (CN¥26.7B) exceed its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 1093 has more cash than its total debt.
Reducing Debt: 1093's debt to equity ratio has increased from 0.6% to 2% over the past 5 years.
Debt Coverage: 1093's debt is well covered by operating cash flow (591.1%).
Interest Coverage: 1093 earns more interest than it pays, so coverage of interest payments is not a concern.